A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses
Vaccines · 02.09.2024 · 12 (9) · 1008
DOI: 10.3390/vaccines12091008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 02.09.2024. Verfasst von Xuejie Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, CAMS Innovation fund for Medical Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The annual co-circulation of two influenza A subtypes, H1N1 and H3N2, viruses in humans poses significant public health threats worldwide. However, the continuous antigenic drift and shift of influenza viruses limited the effectiveness of current seasonal influenza vaccines, necessitating the development of new vaccines against both seasonal and pandemic viruses. One potential solution to this challenge is to improve inactivated vaccines by including multiple T-cell epitopes. In this study, we designed stabilized trimeric recombinant mosaic HA proteins named HAm, which contain the most potential HA T-cell epitopes of seasonal influenza A virus. We further evaluated the antigenicity, hemagglutinin activity, and structural integrity of HAm and compared its immunogenicity and efficacy to a commercial quadrivalent inactivated influenza vaccine (QIV) in mice. Our results demonstrated that the HAm vaccine was able to induce broadly cross-reactive antibodies and T-cell responses against homologous, heterologous, and heterosubtypic influenza-naive mice. Additionally, the HAm antigens outperformed QIV vaccine antigens by eliciting protective antibodies against panels of antigenically drifted influenza vaccine strains from 2009 to 2024 and protecting against ancestral viruses’ lethal challenge. These results suggest that the HAm vaccine is a promising potential candidate for future universal seasonal and pandemic influenza vaccine development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
- National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Shenzhen Nanshan Center for Disease Control and Prevention, Shenzhen 518054, China.
- Center for Disease Control and Prevention of Southern Military Theatre, Guangzhou 510610, China.
- Key Laboratory of Pathogen Infection Prevention and Control (Peking Union Medical College, Ministry of Education), State Key Laboratory of Respiratory Health and Multimorbidity, National Institute of Pathogen Biology of…
ORCID-Profile: Xuejie Liu, Qian Xie, Qijun Liao, Caijun Sun, Huanle Luo, Yuelong Shu
Förderung
- National Key Research and Development Program of China
- CAMS Innovation fund for Medical Sciences
- National Natural Science Foundation of China
- Shenzhen Science and Technology Program
- Science and Technology Planning Project of Guangdong Province, China
- High-Level Project of Medicine in Nanshan, Shenzhen; Sanming Project of Medicine in Shenzhen
Zitieren
APA
Liu, X., Luo, C., Yang, Z., Zhao, T., Yuan, L., Xie, Q., Liao, Q., Liao, X., Wang, L., Yuan, J., Wu, N., Sun, C., Yan, H., Luo, H., & Shu, Y. (2024). A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses. Vaccines, 12(9), 1008. https://doi.org/10.3390/vaccines12091008
Vancouver
Liu X, Luo C, Yang Z, Zhao T, Yuan L, Xie Q, et al. A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses. Vaccines. 2024;12(9):1008. doi:10.3390/vaccines12091008
BibTeX
@article{Liu2024,
author = {Liu, Xuejie and Luo, Chuming and Yang, Zhuolin and Zhao, Tianyi and Yuan, Lifang and Xie, Qian and Liao, Qijun and Liao, Xinzhong and Wang, Liangliang and Yuan, Jianhui and Wu, Nan and Sun, Caijun and Yan, Huacheng and Luo, Huanle and Shu, Yuelong},
title = {A Recombinant Mosaic HAs Influenza Vaccine Elicits Broad-Spectrum Immune Response and Protection of Influenza a Viruses},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {9},
pages = {1008},
doi = {10.3390/vaccines12091008}
}
EUVIMED